Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23532365 | 0.79 | DUT (0.36) | DUT | |
| SCHEMBL571057 | 0.78 | DUT (0.39) | DUT | |
| SCHEMBL14059474 | 0.78 | DUT (0.35) | DUT | |
| SCHEMBL334934 | 0.77 | DUT (0.38) | DUT | |
| Ammonia Solution, Strong SCHEMBL9187414 | 0.77 | DUT (0.38) | DUT | |
| SCHEMBL4717834 | 0.76 | — | — | |
| SCHEMBL1143253 | 0.75 | DUT (0.37) | DUT | |
| SCHEMBL200311 | 0.75 | DUT (0.37) | DUT | |
| SCHEMBL7539972 | 0.75 | DUT (0.37) | DUT | |
| SCHEMBL10930589 | 0.75 | DUT (0.37) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361743-B2 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PFIZER INC (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361743-B2 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PFIZER INC (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1814893-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-07-06 | — | — | US | disclosed |
| WO-2006055070-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | LCLAT1, LAS1L, NRDC | DUT 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.